<DOC>
	<DOCNO>NCT00365508</DOCNO>
	<brief_summary>RATIONALE : Stop-smoking plan , include counsel nicotine replacement therapy , may help smoker quit smoking . It yet know whether counsel nicotine lozenge effective counseling nicotine patch help adult smoker quit smoke . PURPOSE : This randomized phase III trial study counsel nicotine lozenge see well work compare counsel nicotine patch help smoker quit smoking .</brief_summary>
	<brief_title>Counseling Nicotine Replacement Therapy Helping Adult Smokers Quit Smoking</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy behavioral counsel nicotine-replacement therapy either oral nicotine lozenge ( NL ) transdermal nicotine patch ( NP ) , term promote rate smoke cessation ( e.g. , continue abstinence ) , adult smoker . - Examine degree nicotine replacement therapy ( NRT ) preference , desire control NRT dosing , irregular smoking schedule , desire oral preoccupation moderate relative efficacy NL v NP promote smoke cessation . - Evaluate impact NL mediator smoke cessation ( i.e. , reduce craving , diminish withdrawal symptom , cue reactivity , increase perceive control withdrawal symptom ) . Secondary - Compare rate compliance NRT across 2 treatment arm examine compliance rate mediates effect NRT quit rate . - Examine potential role gene relate nicotine dependence gene relate nicotine metabolism enzyme ( e.g. , CYP1A1 ) gene relate dopamine concentration ( e.g. , DRD2 ) . OUTLINE : This randomize , open-label , multicenter study . Participants stratify accord study center . Participants randomize 1 2 intervention arm . All participant undergo smoke cessation counseling week 1 , 3 , 5 , 7 , 9 . Beginning week 3 , participant ask quit smoke 12 week ( week 3-14 ) . - Arm I : Participants apply transdermal nicotine patch 3 different time period week 3-14 ; higher-dose patch apply week 3-8 , medium-dose patch apply week 9-10 , lower-dose patch apply week 11-14 . - Arm II : Participants receive one oral nicotine lozenge every 1-2 hour week 3-8 ( ≥ 9 lozenge per day ) , one lozenge every 2-4 hour week 9-11 ( ≥ 5 lozenge per day ) , 1 lozenge every 4-8 hour week 12-14 ( ≥ 3 lozenge per day ) . The moderating variable ( e.g. , nicotine replacement-therapy [ NRT ] preference smoker 's desire control NRT dose ) assess baseline . The mediating variable ( i.e. , reduce craving , diminish withdrawal symptom , cue reactivity , increase perceive control withdrawal symptom ) assess baseline week 5 , 7 , 9 , within week 14-16 , within week 26-28 . Continuous abstinence measure week 27 . PROJECTED ACCRUAL : A total 700 participant accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Smokes least 10 cigarette day average past year No prior diagnosis cancer ( unless complete treatment AND evidence disease within past 5 year ) Able use nicotine replacement therapy PATIENT CHARACTERISTICS : Able communicate English Must reside geographic area ≥ 6 month Current asthma , ulcer , diabetes allow provided medical clearance participant 's physician obtain No evidence drug alcohol abuse No know HIV positivity No heart disease , include follow : Current diagnosis coronary artery disease Abnormal heart rhythm arrhythmia Heart failure Heart valve disease Congenital heart disease Heart muscle disease cardiomyopathy Pericardial disease Aorta disease Vascular disease Myocardial infarction High blood pressure ( define blood pressure &gt; 140/90 mm Hg ) receive antihypertensive medication History current high blood pressure control antihypertensive medication medical clearance physician allow No allergy adhesive tape latex Not pregnant nursing Negative pregnancy test Fertile participant must use effective contraception ≥ 1 month prior completion study treatment PRIOR CONCURRENT THERAPY : At least 30 day since prior concurrent benzodiazepine ( e.g. , diazepam , alprazolam , lorazepam ) At least 6 month since prior antiretroviral medication At least 6 month since prior concurrent medication depression ( e.g. , phenelzine sulfate , pargyline hydrochloride , tranylcypromine sulfate , paroxetine hydrochloride , sertraline hydrochloride , fluoxetine hydrochloride ) No concurrent antipsychotic ( e.g. , lithium ) theophylline No concurrent substance abuse treatment No concurrent bupropion hydrochloride No concurrent pharmacologic aid form formal assistance smoking cessation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>adult primary liver cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>hypopharyngeal cancer</keyword>
	<keyword>laryngeal cancer</keyword>
	<keyword>lip oral cavity cancer</keyword>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>oropharyngeal cancer</keyword>
	<keyword>paranasal sinus nasal cavity cancer</keyword>
	<keyword>adult acute myeloid leukemia</keyword>
	<keyword>tongue cancer</keyword>
	<keyword>tobacco use disorder</keyword>
</DOC>